Currentblue cross blue shield - tennesseePolicy N/A

Testing for Alpha-1 Antitrypsin Deficiency

Defines coverage criteria and limitations for laboratory testing for alpha-1 antitrypsin (AAT) deficiency, including when serum quantification, phenotyping/proteotyping, and isoelectric focusing meet coverage criteria.

Policy Summary

Payerblue cross blue shield - tennessee

PolicyTesting for Alpha-1 Antitrypsin Deficiency

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionOrder serum AAT quantification and AAT phenotyping/proteotyping when a listed covered clinical indication is present; testing meets coverage once per lifetime.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

once/lifetimecovered frequency

82103,82104,82542,83789procedure codes

2017,2019FDA-cleared tests noted

1997-2024refs span

~20references

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial/One-time Testing

Covered when ANY of the following are met (serum quantification and phenotyping/proteotyping meet coverage once per lifetime):

Covered indications for AAT testing: a) Symptomatic individuals 18 years or older with emphysema, COPD, or asthma; b) Individuals with unexplained liver disease (e.g., chronic hepatitis with or without cirrhosis, chronically elevated aminotransferase levels, portal hypertension, primary liver cancer); c) Individuals with persistent obstruction on pulmonary function tests without identifiable risk factors (e.g., cigarette smoking, occupational exposure); d) Individuals 18 years or older with necrotizing panniculitis; e) Siblings of an individual with known alpha-1 antitrypsin deficiency; f) Individuals with anti-proteinase three (C-ANCA)-positive vasculitis; g) Individuals with bronchiectasis without evident etiology; h) Individuals with neonatal cholestasis.once per lifetime

Serum AAT quantification and AAT phenotyping or proteotyping meet coverage criteria for any one of these indications.

Reflex/Confirmatory Testing

Covered when ALL of the following are met:

When isoelectric focusing (phenotyping) is indicated: Genotype testing is negative for common variants OR there are discordant results between AAT serum levels and proteotype, AND clinical suspicion for AAT deficiency remains.as clinically indicated

Isoelectric focusing/phenotyping meets coverage criteria to resolve discordant or negative genotype results when clinical suspicion persists.

Testing for alpha-1 antitrypsin (AAT) deficiency for any clinical situations not explicitly listed as covered in this policy does not meet coverage criteria.

All other clinical situations not described in this policy are considered not medically necessary and do not meet coverage criteria for testing for AAT deficiency.

Covered Indications

Suspected AAT deficiency — Covered clinical scenarios

Suspected AAT deficiency with any covered clinical scenarios (serum quantification and phenotyping/proteotyping meet coverage once per lifetime):

Clinical scenarios warranting testing: Symptomatic adult (>=18 years) with emphysema, COPD, or asthma; unexplained liver disease (eg, chronic hepatitis ± cirrhosis, chronically elevated aminotransferases, portal hypertension, primary liver cancer); persistent obstruction on pulmonary function testing without identifiable risk factors (eg, cigarette smoking, occupational exposure); adult necrotizing panniculitis; sibling of an individual with known AAT deficiency; C-ANCA (anti-proteinase three)-positive vasculitis; bronchiectasis without evident etiology; neonatal cholestasis.once per lifetime

Serum AAT quantification and AAT phenotyping/proteotyping meet coverage criteria for any one of these scenarios.

Discordant or negative genotype with continued clinical suspicion

Discordant genotype/serum results or negative genotype for common variants with continued clinical suspicion:

Confirmatory phenotyping indication: When genotype testing is negative for common variants OR there are discordant results between AAT serum levels and proteotype, AND clinical suspicion for AAT deficiency remains, isoelectric focusing (phenotyping) meets coverage criteria.as clinically indicated

Specifically addresses use of isoelectric focusing/phenotyping when genotyping or serum levels are inconclusive.

References supporting testing for suspected A1ATD

References supporting testing for suspected A1ATD in the listed clinical contexts (diagnostic evaluation and longitudinal outcomes):

Supporting references: Selected references include diagnostic algorithms and outcome studies that inform testing in COPD, unexplained liver disease, neonatal cholestasis, and family-history contexts (eg, Snyder et al. 2006; Soriano et al. 2018; Stoller et al.; Teckman et al. 2020, 2023).

These citations support the covered indications and clinical rationale for testing.

Frequency Limits

inv-20: Serum AAT quantification and AAT phenotyping/proteotyping — once per lifetime

Covered testsSerum alpha-1 antitrypsin (AAT) quantification and AAT phenotyping or proteotyping

Frequency limitOnce per lifetime

Applicable situationsMeets coverage once per lifetime when patient meets any listed indication (e.g., symptomatic adults with emphysema/COPD/asthma; unexplained liver disease; persistent obstruction without risk factors; adult necrotizing panniculitis; sibling of known AAT deficiency case; C-ANCA–positive vasculitis; bronchiectasis without etiology; neonatal cholestasis)

inv-21: Frequency limits — additional frequency info

Primary frequency ruleSerum AAT quantification and AAT phenotyping/proteotyping: once per lifetime (coverage applies to any one covered indication)

Reflex/confirmatory testing frequencyIsoelectric focusing/phenotyping is covered as clinically indicated when genotype is negative for common variants or results are discordant with serum levels

Benefit-dependence noteApplication of these frequency limits is dependent on the individual member's benefit coverage and applicable Medicare/Medicaid rules

Provider Actions & Billing Notes

Documentation Required

Coverage Criteria and Code Applicability

For AAT testing, coverage and code applicability: Serum AAT quantification and AAT phenotyping/proteotyping (including isoelectric focusing/phenotyping when genotype is negative or discordant with serum levels) meet coverage criteria once per lifetime when ordered for any of the listed clinical indications (see items below). Document the specific covered indication in the clinical record at the time of testing.

Covered once per lifetime for symptomatic adults (≥18 years) with emphysema, COPD, or asthma
Covered for unexplained liver disease (eg, chronic hepatitis ± cirrhosis, chronically elevated aminotransferases, portal hypertension, primary liver cancer)
Covered for persistent obstruction on pulmonary function testing without identifiable risk factors (eg, cigarette smoking, occupational exposure)
Covered for adults (≥18 years) with necrotizing panniculitis
Covered for siblings of an individual with known AAT deficiency
Covered for individuals with C‑ANCA (anti‑proteinase 3)–positive vasculitis
Covered for individuals with bronchiectasis without evident etiology
Covered for individuals with neonatal cholestasis
Covered when genotype for common variants is negative or discordant with serum level and clinical suspicion remains (isoelectric focusing/phenotyping)

Denial Risk

Non‑covered Indications

Testing that does not meet coverage criteria: any indication not explicitly listed above does NOT meet coverage criteria and may be denied. Providers should avoid ordering AAT testing for indications outside the covered list unless additional supportive clinical documentation justifies medical necessity.

All other situations not described in the covered indications DO NOT MEET COVERAGE CRITERIA

Note

Prior Authorization

No prior authorization requirement is stated in the referenced policy text. Verify member benefit documents for plan-specific prior authorization rules at time of service.

Note

LDT Regulatory Context

Laboratory‑developed tests (LDTs) such as in‑house AAT assays are commonly used and regulated under CLIA as high‑complexity tests; document laboratory validation and methodology in the test report as applicable.

LDTs are not FDA‑cleared but are acceptable when validated under CLIA '88

Documentation Required

Supporting Clinical Documentation

Supporting clinical documentation: The medical record must document one of the covered clinical indications at the time of testing (eg, symptomatic emphysema/COPD/asthma in an adult, unexplained liver disease, persistent unexplained obstructive PFTs, necrotizing panniculitis, sibling of affected individual, C‑ANCA–positive vasculitis, bronchiectasis of unknown cause, neonatal cholestasis, or continued suspicion after negative/discordant genotype). Include relevant signs, symptoms, diagnostic test results (eg, PFTs, liver function tests), family history, and prior genotype or serum AAT levels when applicable.

Document specific covered indication in chart
Attach prior genotype or AAT level results when ordering phenotyping/isolectric focusing for discordant cases
Include relevant diagnostic data (PFTs, aminotransferases, imaging, pathology)

Denial Risk

Denial‑Risk Note

Provider action notes / denial‑risk reminder: There are no explicit denial‑risk statements in the reference entries beyond the general policy that tests outside the listed indications do not meet coverage criteria. Nonetheless, ordering outside covered indications or failing to document a covered indication increases risk of denial.

Failure to document a covered indication may result in claim denial
When in doubt, confirm medical necessity with payer or include detailed clinical rationale on requisition

Note

Provider Action — Additional Instructions

Fallback provider instruction: If further provider instructions are needed, consult the full policy text and references (eg, diagnostic algorithm literature) and the member's specific benefit contract for any plan‑level requirements.

Refer to diagnostic algorithm literature (eg, Snyder et al., Clin Chem 2006) for testing sequence guidance
Confirm plan benefits prior to testing

Definitions

inv-15: AAT phenotyping / proteotyping — phenotyping via isoelectric focusing; proteotyping (Z and S alleles) via LC-MS/MS.

Phenotyping methodIsoelectric focusing (AAT phenotyping should be performed using isoelectric focusing)

Proteotyping methodAAT proteotyping for Z and S alleles should be performed using liquid chromatography–tandem mass spectrometry (LC-MS/MS)

PurposeDistinguishes AAT protein variants and identifies common pathogenic alleles (Z and S) when needed for diagnosis or confirmation

inv-16: Alpha-1 antitrypsin deficiency — definition and associated clinical manifestations (pulmonary emphysema/COPD, liver disease, neonatal cholestasis).

DefinitionAlpha-1 antitrypsin deficiency (AATD) is a genetic condition causing deficient or defective production of the AAT protease inhibitor that can affect the lungs, liver, and skin

Pulmonary manifestationsAssociated with early-onset pulmonary emphysema/COPD due to unopposed proteolytic breakdown of lung elastic tissue

Hepatic manifestationsAssociated with liver disease including neonatal cholestasis and increased risk of cirrhosis; heterozygous Pi*Z carriage can increase cirrhosis risk

OpenPayer

Testing for Alpha-1 Antitrypsin Deficiency

Coverage Criteria

Covered Indications

Frequency Limits

Applicable Codes

Provider Actions & Billing Notes

Ordering Requirements

Not Covered

Definitions

Background

82103	Alpha-1-antitrypsin; total.
82104	Alpha-1-antitrypsin; phenotype.
82542	Column chromatography, includes mass spectrometry, if performed (eg, HPLC, LC, LC/MS, LC/MS-MS, GC, GC/MS-MS, GC/MS, HPLC/MS), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen.
83789	Mass spectrometry and tandem mass spectrometry (eg, MS, MS/MS, MALDI, MS-TOF, QTOF), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen.